

# Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience

## Authors

---

Aakanksha Naik,<sup>1</sup> Babita Kataria,<sup>2</sup> Vinod Sharma,<sup>2,3</sup> Aparna Sharma,<sup>2</sup> Atul Batra,<sup>1</sup> Kanupriya Bhatia,<sup>1</sup> Bhoor Singh,<sup>1</sup> Anita Chopra,<sup>4</sup> Diptiranjana Rout,<sup>5</sup> Hari Sagiraju,<sup>6</sup> Rounik Talukdar,<sup>6</sup> Sarjana Tiwari<sup>7</sup> and Akash Kumar<sup>2</sup>

<sup>1</sup>Department of Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi; <sup>2</sup>Department of Medical Oncology, National Cancer Institute, AIIMS - Jhajjar Campus, All India Institute of Medical Sciences, District - Jhajjar, Haryana; <sup>3</sup>HCG Cancer Institute, Jaipur, Rajasthan; <sup>4</sup>Department of Laboratory Oncology, IRCH, All India Institute of Medical Sciences, New Delhi; <sup>5</sup>Department of Transfusion Medicine, National Cancer Institute, AIIMS - Jhajjar Campus, All India Institute of Medical Sciences, District - Jhajjar, Haryana; <sup>6</sup>Department of Preventive Oncology, National Cancer

Institute, AIIMS - Jhajjar Campus, All India Institute of Medical Sciences, District - Jhajjar, Haryana and <sup>7</sup>Department of Hematopathology, MAX Super-specialty hospital, Patparganj, New Delhi, India

Correspondence:

A. KUMAR - akashjha08@yahoo.com

<https://doi.org/10.3324/haematol.2025.289048>


Received: September 1, 2025.

Accepted: December 17, 2025.

Early view: December 24, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 



Supplementary figure 1: Kaplan Meier curve depicting a) overall survival, b) event-free survival and, c) relapse-free survival in the FLT3-ITD mutated cohort



Supplementary table 1: Baseline characteristics

variables	Patients (n=80)
Age in Years [Median (Range)]	33.5 (17-68)
Sex	
Male	37 (53.8%)
Female	43 (46.3%)
Symptom Duration in Months [Median (Range)]	1 (0.2-6.0)
Bone marrow blasts percentage [Median (Range)]	74 (10-100)
ELN 2022 Risk stratification	
Favorable risk (FR)	27 (33.8%)
Intermediate Risk (IR)	40 (50.0%)
Adverse Risk (AR)	13 (16.3%)
Selected Molecular alteration	
RUNX1/RUNX1T1	12
CBFB/MYH11	5
NPM1	9
bZIP CEBPA	9
CEBPA	3
FLT3	26
KIT	4
ASXL1/2	4
RUNX1	5
IDH1	6
IDH2	2
BCOR / BCORL1	3
WT1	11
GATA2	1
DNMT3A	3
KMT2A	3
HNRNPH1-ERG	1

CSF3R	1
NRAS / KRAS	18
TP53	1
SF3B1	1
TET2	2
DEK-NUP214	3
IKZF1	1
PTPN1	2
RAD21	1
ETV6	1
SETD2	1
PRDM16/SKI	1
NUP98/NSD1	1
CCND3	2
JAK2	1
JAK3	2